Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B.
Yasuhiro Hamatani, Brian L Claggett, Sarah A M Cuddy et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the effects of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), stratified by baseline tafamidis use. Among 654 participants, those on tafamidis showed a rate ratio of 0.79 for the primary outcome of all-cause mortality and cardiovascular events, compared to 0.67 for those not on tafamidis, indicating a reduced effect size in the combination therapy group.
Key findings
- 40% of participants were on tafamidis at baseline.
- Vutrisiran reduced the primary outcome rate ratio to 0.79 with tafamidis and 0.67 without.
- No statistically significant interaction was found based on tafamidis use (P interaction = 0.55).
- Improvements in KCCQ-OSS were attenuated in patients receiving tafamidis.
Why it matters
Understanding the differential effects of combination therapies in ATTR-CM is crucial for optimizing treatment strategies. This study highlights the need for further research into the efficacy of combining vutrisiran with tafamidis.